Multibagger Pharma Company Acquires 12.05% Minority Stake in Gennova; Takes Ownership to 100%

On Tuesday, Indian equity benchmarks ended lower, with the benchmark Nifty 50 index declining 0.66 per cent or 158.95 points to close at 24,052.05. In contrast, Emcure Pharmaceuticals share price ended 0.94 per cent higher or Rs 16.80 at Rs 1,810.10, following the company's announcement regarding the consolidation of its ownership in biopharma subsidiary Gennova Biopharmaceuticals Limited.

Emcure To Acquire Entire 12.05 Per Cent Minority Stake In Gennova

Emcure Pharmaceuticals announced the consolidation of its shareholding in Gennova Biopharmaceuticals alongside a leadership transition as the company sharpens its focus on biologics and biosimilars. The company informed the stock exchanges about the development through a press release dated July 13, 2026.

Emcure is acquiring the entire 12.05 per cent minority stake in Gennova held by Dr Sanjay Singh and others. Following the stake acquisition, Emcure's ownership in Gennova will increase to 100 per cent, making Gennova a wholly owned subsidiary of the company.

Gennova To Focus On Biologics And Biosimilars

Under the consolidated ownership structure, Gennova will focus on its biologics franchise, including Elaxim/TENECTASE, Vintor, Xgrast/PEGEX and Hamsyl. The company will also focus on biosimilars development and adjacent therapeutic platforms.

Gennova plans to leverage its established mammalian and microbial biomanufacturing platforms to support its biologics and biosimilars operations.

Samit Mehta To Lead Gennova's Next Phase Of Growth

Gennova Biopharmaceuticals will be led by Samit Mehta as the company enters its next phase of growth. The leadership transition forms part of Emcure's strategy to simplify Gennova's ownership and sharpen its strategic focus on biologics and biosimilars.
Also Read - Kirloskar Group-Backed Industrial Products Company Secures Rs 149.59 Crore International Order for Vertical Pumps and Spares

Management Commentary

Commenting on the announcement, Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, said, “We thank Dr. Sanjay Singh for his nearly two decades of exceptional scientific leadership at Gennova. His stewardship has built platforms, products, and a culture that will continue to fulfil Gennova's mission of transforming healthcare. With this stake acquisition, we simplify Gennova's ownership, sharpen its strategic focus, and position it under Mr. Samit Mehta's leadership for its next phase of growth in biologics and biosimilars.”

Samit Mehta, Whole Time Director and CEO of Gennova Biopharmaceuticals, said, “As part of the One Emcure framework, Gennova will continue to anchor the Group's biologics and biosimilars capabilities. Our work will complement Emcure's broader R&D and pipeline priorities, with a focus on execution, quality and disciplined development across our chosen therapy areas.”

No Material Impact On Consolidated Financials

The transaction is not expected to have a material impact on Emcure Pharmaceuticals' consolidated financials or its capital allocation framework.

The company stated that its deleveraging trajectory, capital expenditure plans and research and development investment plans remain unchanged.

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is a Pune-headquartered pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Established in 1981, the company develops and manufactures differentiated pharmaceutical products across several major therapeutic areas.

Emcure was ranked as the 13th largest pharmaceutical company in India in terms of domestic sales for MAT March 2026 and has a presence in more than 70 countries globally, including Europe and Canada.

Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.